Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How do we make progress in phenotyping patients with lower urinary tract such as overactive bladder and underactive detrusor, including using urine markers and microbiome data, to personalize therapy? ICI-RS 2023-Part 2.
Finazzi Agrò E, Rosato E, Wagg A, Sinha S, Fede Spicchiale C, Serati M, Mancini V, de Rijk M, Tarcan T, Wein A, Abrams P, Bou Kheir G. Finazzi Agrò E, et al. Among authors: wein a. Neurourol Urodyn. 2024 Aug;43(6):1272-1282. doi: 10.1002/nau.25379. Epub 2024 Jan 4. Neurourol Urodyn. 2024. PMID: 38178629 Review.
Beyond the urothelium: Interplay between autonomic nervous system and bladder inflammation in urinary tract infection, bladder pain syndrome with interstitial cystitis and neurogenic lower urinary tract dysfunction in spinal cord injury-ICI-RS 2023.
Wyndaele M, Charrua A, Hervé F, Aronsson P, Grundy L, Khullar V, Wein A, Abrams P, Cruz F, Cruz CD. Wyndaele M, et al. Among authors: wein a. Neurourol Urodyn. 2024 Aug;43(6):1283-1292. doi: 10.1002/nau.25310. Epub 2023 Oct 25. Neurourol Urodyn. 2024. PMID: 37876314 Review.
Could a better understanding of the underlying pathophysiologies lead to more informed treatment choices in patients with lower urinary tract dysfunction due to an acontractile or underactive detrusor? ICI-RS 2023.
Sinha S, Everaert K, Kheir GB, Roberts N, Solomon E, Belal M, Selai C, Perrouin-Verbe MA, Spicchiale CF, Wein A, Abrams P. Sinha S, et al. Among authors: wein a. Neurourol Urodyn. 2024 Aug;43(6):1381-1390. doi: 10.1002/nau.25329. Epub 2023 Nov 13. Neurourol Urodyn. 2024. PMID: 37960931 Review.
How do we make progress in phenotyping patients with LUT such as OAB and underactive detrusor, including using urine markers and microbiome data, in order to personalize therapy? ICI-RS 2023: Part 1.
Finazzi Agrò E, Rosato E, Wagg A, Sinha S, Fede Spicchiale C, Serati M, Mancini V, de Rijk M, Tarcan T, Wein A, Abrams P, Bou Kheir G. Finazzi Agrò E, et al. Among authors: wein a. Neurourol Urodyn. 2024 Aug;43(6):1261-1271. doi: 10.1002/nau.25377. Epub 2024 Jan 4. Neurourol Urodyn. 2024. PMID: 38178627 Review.
What is the best first choice oral drug therapy for OAB?
Sahai A, Robinson D, Abrams P, Wein A, Malde S. Sahai A, et al. Among authors: wein a. Neurourol Urodyn. 2024 Aug;43(6):1328-1336. doi: 10.1002/nau.25397. Epub 2024 Jan 25. Neurourol Urodyn. 2024. PMID: 38270332 Review.
1,456 results